Seeing most of the studies in various parts of the world related to this shows that TP53 mutation is an important marker of poor prognosis and predictor of lung cancer, especially in cases of NSCLC with EGFR mutations.50–54 By comparing TP53 mutation group with TP53 wild-type group, a recent meta-analysis on this issue confirmed worse OS of TP53 in EGFR mutant lung cancers by 1.7 times in comparison to wild-type group (hazard ratio 1.73, 95% CI 1.22-2.44, P=0.002).54 This evidence concerns the gene TP53 and non-small cell lung carcinoma.